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Finasteride Quantification in Human Plasma by High-
Performance Liquid Chromatography Coupled to 
Electrospray Ionization Tandem Mass Spectrometry. 
Application to a Comparative Pharmacokinetics Study
extensive hepatic metabolism to a series of 5 
metabolites, of which 2 are active and possess 
less than 20 % of the 5 alpha-reductase activity of 
finasteride, which are eliminated through the 
bile and urine [6]. Its absolute bioavailability is 
63 %, (range from 33 to 108 %) [7]. Maximum 
plasma concentration is reached at 1–2 h [7], and 
it is approximately 90 % bound to plasma protein. 
The elimination half-life averages 6–8 h.
Several liquid chromatographic methods with 
UV detection have been developed [8–13]. How-
ever, HPLC methods for finasteride measurement 
in plasma suffer from limitations such as low 
sensitivity, poor selectivity and being time-con-
suming due to complex sample preparation 
 procedures.
Analytical methods describing the quantification 
of finasteride using a liquid chromatography cou-
pled to a tandem mass spectrometry analysis 
have also been described [14–19]. Although the 
HPLC coupled to the triple-quadrupole mass 
spectrometry analysis (LC-MS/MS) is not always 
affordable for routine measurements in many 
laboratories, LC-MS/MS has become the widely 
used analytical tool for the pharmacokinetic 
Introduction
▼
Androgens are essential for prostatic develop-
ment, growth and function. However, later in life 
they have a significant role in the pathogenesis of 
Benign prostatic hyperplasia (BPH) and prostate 
cancer [1]. The enzyme 5a-reductase (5aR) con-
verts testosterone (TS) into a more potent andro-
gen, dihydrotestosterone (DHT). Therefore, 
tissues with a high concentration of these 
enzymes, such as the prostate, act to concentrate 
the effects of circulating testosterone. Thus, the 
inhibition of DHT conversion offers the potential 
to prevent, delay or possibly treat BPH or prostate 
cancer, providing a different approach for their 
management. Finasteride, a synthetic 4-azaster-
oid, inhibits the action of the 5α-reductase 
enzyme [2, 3]. Treatment with finasteride results 
in a significant reduction of prostatic and circu-
lating DHT levels compared with baseline [4] and 
is widely used for the treatment of BPH. Finas-
teride may also be used to prevent hair loss in 
younger man [5].
Finasteride is well absorbed and widely distrib-
uted after oral administration. It undergoes 
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Abstract
▼
A specific, fast and sensitive LC-MS/MS assay was 
developed for the determination of finasteride in 
human plasma using betamethsone dipropionate 
as the internal standard (IS). The limit of quanti-
fication was 1.0 ng/ml and the method was linear 
in the range of 1.0–25.0 ng/ml. The retention times 
were 0.75 min for finasteride and 0.85 min for IS. 
Method intra-batch precision and accuracy ranged 
from 3.6 to 7.1 %, and 96.6 to 103.9 %, respectively. 
Inter-batch precision ranged from 2.5 to 3.4 %, 
while Inter-batch accuracy ranged from 100.3 to 
103.5 %.
The analytical method was applied to evaluate 
the pharmacokinetic and relative bioavailability 
of 2 different pharmaceutical formulations con-
taining 1.0 mg of finasteride. This study evalu-
ated 38 volunteers in a randomized, 2-period 
crossover study with 7 days washout period 
between doses. The geometric mean and respec-
tive 90 % CI of finasteride test/reference percent 
ratios were 95.68 % (91.2 – 104.6 %) for Cmax, 
97.5 % (92.1 –103.3 %) for AUC0-t and 98.1 
(92.67 − 103.8) for AUC0-inf. Based on the 90 % 
confidence interval of the individual ratios (test 
formulation/reference formulation) for Cmax and 
AUC0-inf, it was concluded that the test formula-
tion is bioequivalent to the reference one with 
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study and quantification of drugs and its metabolites in biologi-
cal samples due to its high sensitivity and selectivity.
To allow for the correct comparison of newer finasteride formu-
lation with a reference one, we validated a LC-MS/MS method 
with good selectivity, linearity range, precision, accuracy, and 
lower limit of quantification (LLOQ) for the quantification of fin-
asteride in plasma samples using betamethasone dipropionate 
as internal standard. This method was applied to evaluate the 
comparative bioavailability in 38 healthy volunteers. All volun-
teers received a single 1.0 mg tablet orally corresponding to the 
test finasteride or reference formulation, following an open, 




Finasteride (batch # F1E139) and the internal standard betame-
thasone dipropionate (batch # L0G377) were obtained from USP, 
Rockville, MD. Ultrapure water was obtained from a Milli-Q sys-
tem (Millipore, Sao Paulo, Brazil). The HPLC grade methanol and 
acetonitrila were obtained from Tedia Brasil (Rio de Janeiro, RJ, 
Brazil). Ethyl acetate and hexane were purchased from Quemis 
(Joinville, SC, Brazil). Formic acid was purchased from Merck 
Brazil (Rio de Janeiro, RJ, Brazil Sodium hydroxide was pur-
chased from Haloquímica (São Paulo, SP, Brazil). Blank human 
blood was collected from healthy, drug-free volunteers. Plasma 
was obtained by centrifugation of blood treated with the antico-
agulant Heparin (BD Vacutainer®, BD, Franklin Lakes, NJ USA) 
and stored at  − 20 °C until needed for preparation of calibration 
standards, quality control (QC) samples, and plasma blanks. 
Human Plasma samples (normal, hyperlipemic and hemolyzed) 
came from distinct drug free subjects.
Instrumentation and detection
The HPLC system used was an Agilent 1200 series (Agilent tech-
nologies, Waldbronn, Germany). A mass spectrometer Agilent 
6460 triple quadrupole instrument (Agilent technologies, Wald-
bronn, Germany) was used. Electrospray positive mode with 
Multiple Reaction Monitoring (MRM) was used for detection. 
For finasteride, [M + H] +  (m/z 373.5) was monitored as the pre-
cursor ion and a fragment at m/z 305.2 was chosen as the prod-
uct ion. For Betamethasone dipropionate, the [M + H] +  (m/z 
505.3) was monitored as the precursor ion and a fragment at 
m/z 411.2 was monitored as the product ion. Mass parameters 
were optimized as gas temperature 325 °C, nebulizer gas 15 psi, 
capillar voltage 2 500 V, cone voltage 150 V, gas flow rate 11 L/mi, 
cell accelerator 7 V, declustering potential 40 V, dwell time 0.2 s 
for each transition, collision energy 28 eV for finasteride and 
4 eV for Betamethasone dipropionate.
Preparation of standards and quality control (QC) 
samples
Standard stock solutions at 1.0 mg/mL of finasteride and Beta-
methasone dipropionate were prepared in acetoniltrila-water 
(70:30, v/v). Spiking solutions were then prepared by diluting 
the stock solution in acetoniltrila-water (70:30, v/v) to form 8 
solutions 10 times concentrated. Standard and spiking solutions 
were stored under refrigerator conditions (2–8 °C) until analysis. 
Plasma standards were prepared by adding 200 µL of each of the 
12 spiking solutions to 200 µL samples of human plasma. This 
process yielded calibration standards with nominal concentra-
tions of 0.1, 0.3, 1.0, 5.0, 10.0, 15.0, 20.0 and 25.0 ng/mL and con-
trol samples of 0.3, 10.0, 20.0 ng/mL of finasteride in human 
plasma. Both calibrators and quality control samples were 
freshly prepared at the day of analysis and used within the sta-
bility period determined. Quality control samples for stability 
testing were stored as indicated in section “Stability”.
Sample preparation
Liquid-liquid extraction was used to isolate finasteride and Beta-
methasone dipropionate from human plasma. A volume of 
100 μl of Betamethasone dipropionate (5.0 ng/mL), 200 μL of 
plasma sample (respective concentration) and were added to 
polypropylene tubes, vortexed briefly and placed in an ice bath. 
This process was followed by addition of 50 μL of 0.1 M sodium 
hydroxide, 1.5 mL of extraction solvent (ethyl acetate-hexane, 
50:50, v/v) and vortexed for approximately 10 s. Further samples 
were centrifuged at 3 000 rpm for 1 min at 4 °C. Samples were 
then frozen in dry ice bath and the supernatant from each sam-
ple was transferred into polypropylene tubes and evaporated to 
dryness under nitrogen flow at 40 °C. Finally, dried residue from 
each tube was reconstituted with 100 μL of reconstitution solu-
tion (acetonitrila-water with 0.1 % of formic acid, 90:10, v/v) and 
vortexed briefly. Subsequently, 20 μL of sample from each tube 
was transferred into auto sampler vials and injected into the 
LC-MS/MS.
Chromatographic conditions
A Eclipse XDB-C8, 100 × 2.1 mm, 3.5 μm, was selected as the ana-
lytical column. The mobile phase composition was 0.1 % formic 
acid: acetonitrile (20:80 v/v). The flow rate of the mobile phase 
was set at 0.5 mL/min. The column temperature was set at 40 °C. 
Betamethasone dipropionate was used as the appropriate inter-
nal standard. The retention time of finasteride and Betametha-
sone dipropionate were found to be 0.75 ± 0.1 min and 
0.85 ± 0.1 min, respectively with a total run-time of 2 min for 
each sample.
Selectivity and lower limit of quantification
To evaluate method specificity, blank human plasma obtained 
from 6 different subjects was prepared, analyzed, and examined 
for response of the analyte and IS chromatographic profiles. The 
LLOQ was established at a level for which the response was 
greater than 5 times the blank response. The accuracy and preci-
sion criteria required that the LLOQ calibration standard accu-
racy and precision average within 20 % of target with a CV 
of  ≤ 20 % for 5 validation batches.
The calculations were based on 6 replicates of LLOQ sample, 
whose precision and accuracy were determined intra-day and 
inter-day.
Linear dynamic range and over-range samples
Method linearity was investigated by analyzing a set of calibra-
tion standards with each of the 3 validation batches. Calibration 
curves were constructed by plotting area ratios (analyte/IS) vs. 
analyte concentrations for the 8 calibration standards and per-
forming a weighted, 1/x2 linear regression analysis. Linearity 
was evaluated by examining the correlation coefficients of the 
calibration curves and by determining the accuracy of the cali-
bration standards when calculating their concentrations using 
the regression curve parameters. Accuracy was determined by 
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tration and multiplying by 100 to express the value as a percent-
age.
Accuracy and precision
During method validation, QC samples were prepared by spiking 
known amounts of finasteride into normal human plasma at 4 
distinct levels. These levels were: LLOQ-QC (QC at lower level of 
concentration), 0.1; QCL (QC at low level), 0.3; QCM (QC at 
medium level of concentration), 10.0; and QCH (QC at high level 
of concentration), 20.0 ng/mL plasma for finasteride. Accuracy 
and precision were determined during analysis of 3 validation 
batches, with each batch containing 6 replicates at each QC level. 
The accuracy and precision criteria required that for QCs above 
the LLOQ, accuracy and precision must average within 15 % of 
target with a CV of ≤ 15 % for 3 validation batches. As described 
in section “Selectivity and lower limit of quantification”, the cri-
teria for LLOQ calibration standard accuracy and precision must 
average within 20 % of target with a CV of  ≤ 20 %.
Throughout the course of clinical sample analysis, accuracy and 
precision of the assay were continually monitored with QC sam-
ples prepared at 3 levels. For each analytical run of the study 
samples, QC samples were included at the low, medium, and 
high levels previously described, with at least 3 replicates at 
each level per run.
Autosampler carry-over
Immediately following injection of the highest calibration stand-
ard containing 25.0 ng/mL finasteride, three 20 µL injections of a 
1 % formic acid blank or freshly extracted blank plasma samples 
were sequentially performed. All analyte and internal standard 
peak windows were examined for the presence of measurable 
response due to carry-over. Peaks were integrated and the per-
cent carry-over was computed by dividing these areas by the 
corresponding peak area produced upon injection of the LLOQ.
Extraction efficiency and ionization suppression
Analyte and internal standard extraction efficiencies from 
human plasma were determined by comparing the LC-MS/MS 
response for each analyte and internal standard when analyzing 
plasma samples spiked with the compounds prior to extraction 
vs. the response obtained when the compounds were added to a 
prepared blank plasma matrix after extraction and immediately 
prior to reconstitution. 3 replicates were spiked at the QCL, QCM, 
and QCH levels before and after LLE.
Signal loss from all sources, including ionization suppression 
and extraction from plasma, was determined by directly com-
paring the LC-MS/MS responses for analyte and internal stand-
ard produced from the analysis when the compounds were 
added to a prepared blank plasma matrix after extraction with 
the corresponding responses obtained from injection of the 
compounds diluted in solvent. The mean response for each com-
pound in plasma samples spiked at QCL, QCM, and QCH levels 
was determined from 3 replicates.
Stability
Stability of finasteride and Betamethasone dipropionate was 
determined under a variety of storage conditions chosen to sim-
ulate those expected to be encountered during the collection, 
storage, and analysis of study samples. For stability studies, QCL 
and QCH concentrations were used for evaluation of the storage 
conditions. A minimum of 3 replicate measurements were per-
formed at each level and recoveries were determined vs. a freshly 
prepared calibration curve and expressed in percentage of deg-
radation.
Initially, stability was evaluated after 3 freeze-thaw cycles 
at  − 20 °C. In each cycle, frozen samples were allowed to thaw at 
controlled ambient temperature (22 °C) and were subsequently 
refrozen for 24 h. Aliquots of all samples were quantified at the 
end of the third freeze-thaw cycle. The post processing stability 
was assessed for a 25-h period. In this assay, plasma samples 
spiked with QCs concentration were subjected to processing and 
stored after liquid-liquid extraction at room temperature prior 
to analyze by LC-MS/MS.
To evaluate the short term stability samples were initially 
thawed at room temperature (22 °C) and remained on the bench 
top for a time exceeding the maximum period of time expected 
for routine sample preparation (23 h). Long-term stability was 
evaluated in spiked human plasma stored at  − 20 °C for 185 days.
Finstareide stock solutions were prepared as described, stored at 
4 °C and 5 replicates were evaluated after 3 days. In addition, 
analite and IS work solutions were stored at room temperature 
and evaluated after 9 h.
Pharmacokinetic study
The analytical method developed here was applied to evaluate 
plasma pharmacokinetic of finasteride from 2 tablet formula-
tions of 1.0 mg in healthy volunteers. 38 healthy male volunteers 
aged between 18 and 45 years and index of corporal mass within 
18.72 and 29.73 were selected for the study after assessment of 
their health status by clinical evaluation (physical examination, 
ECG) and the following laboratory tests: blood glucose, urea, cre-
atinine, AST, ALT, alkaline phosphatase, γ-GT, total bilirubin, 
albumin and total protein, triglyceride, total cholesterol, uric 
acid, hemoglobin, hematocrit, total and differential white cell 
counts and routine urinalysis. All subjects were negative for HIV, 
HCV and HBV. All subjects gave written informed consent and 
the study was conducted in accordance with the revised Decla-
ration of Helsinki, the rules of Good Clinical Practice (ICH-GCP) 
and the Resolutions No.196/96 and 251/97 of National Health 
Council – Health Ministry, Brazil [20]. The clinical protocol was 
approved by the Research Ethics Committee of University of 
Campinas – Unicamp, São Paulo, Brazil.
The study was a single-dose, 2-way randomized crossover 
design with a 7 days washout period between the doses. The 
volunteers entered the Clinical Pharmacology Unit 10 h before 
drug administration and left the Unit 14 h after the beginning of 
sampling. For further sampling the volunteers returned to the 
clinical facility following the 24 h interval until the last time 
defined in the clinical protocol. After the predose sampling, each 
volunteer received a single dose of finasteride (1.0 mg of either 
tablet formulation) with 200 mL of water. The volunteers were 
then fasted for 4 h, after which period a standard lunch was 
served. No other food was permitted during the ‘in-house” 
period and liquid consumption was allowed ad libitum after 
lunch (with the exception of xanthine-containing drinks, includ-
ing tea, coffee, and soft drinks). The subjects were monitored 
throughout the study and the formulations were considered to 
be well tolerated. Blood samples were collected by indwelling 
catheter into heparin containing tubes before dosing and 20, 
40 min and also 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24 and 
36 h post-dosing. The blood samples were centrifuged at 2 000 × g 
for 10 min at 4 °C and the plasma separated and stored in a poly-
propylene cryogenic screw capped tubes at  − 20 °C until ana-
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Statistical analysis
Bioequivalence between the 2 formulations was assessed by cal-
culating individual test/reference ratios for the peak of concen-
tration (Cmax), area under the curve (AUC) of plasma 
concentration until the last concentration observed (AUClast) and 
the area under the curve between the first sample (pre-dosage) 
and the area under the curve extrapolated to infinity (AUC0–inf). 
Cmax and the time taken to achieve this concentration (Tmax) 
were obtained directly from the curves. The areas under the fin-
asteride plasma concentration vs. time curves from 0 to the last 
detectable concentration (AUClast) were calculated by applying 
the linear trapezoid rule.
The elimination rate constant (kel) was obtained as the slope of 
the linear regression of the log-transformed concentration val-
ues vs. time data in the terminal phase. The elimination half-life 
(t1/2) was calculated as 0.693/kel. The AUC0–inf was calculated as 
AUClast + Ct/kel, where Ct was the last measurable concentration.
Statistical calculations were defined at the level of P ≤ 0.10 and 
bioequivalence was reached when the 90.0 % confidence interval 
for Cmax, AUClast and AUC0-inf felt within the range of 80.0–125.0 % 
defined by both the Food and Drug Administration (FDA) and the 
National Sanitary Surveillance Agency (ANVISA). The software 
used included Equivtest® 2.0, MS Excel® 97, Tinn-R1.1, Win-
Edit® 2.0 and Scientific Work Place® 5.0.
Results and Discussion
▼
The method for quantification of finasteride in human plasma 
was validated using the described procedures based on the Fed-
eral Guidance for Industrial Bioanalytical Method Validation 
[21] and the Brazilian National Sanitary Surveillance Agency 
(ANVISA) [22], prior to analysis of study samples as a require-
ment for drug quantification in pharmacokinetic studies.
To allow for the correct comparison of newer finasteride formu-
lation with reference one, we validated a LC-MS/MS method 
with good selectivity, linearity range, precision, accuracy, and 
lower limit of quantification for the quantification of finasteride 
in plasma samples using betamethasone dipropionate as inter-
nal standard.
Product ion spectra and chromatography
The chemical structures of finasteride and the internal standard 
betamethasone dipropionate are displayed in  ●▶ Fig. 1 along 
with the respective product ion mass spectra. These spectra 
were collected during infusion of the molecules under collision 
conditions used for quantification and the selected precursor to 
product ion transitions monitored with the assay is indicated.
For the determination of finasteride, the isocratic chromato-
graphic condition was developed using a combination of solvent 
mixture in the mobile phase along with others parameters that 
provided good specificity to the method and eluted the analyte 
and IS with good peak shapes in a reasonably short time scale. 
The LC-MS/MS data were collected through 2.0 min but both 
compounds eluted close to 1.0 min after injection (0.75 min for 
finasteride and 0.85 min for betamethsone dipropionate). Typi-
cal peak shapes and retention times of the SRM chromatograms 
obtained from individual samples spiked with finasteride or the 
IS are shown in  ●▶ Fig. 2. The chromatography described here is 
the fastest compared to the similar methods described in the lit-
erature. The closest run time (3 min) was described by Constan-
zer et al. using HPLC coupled to atmospheric-pressure 
chemical-ionization tandem mass spectrometry [15] and 
Phapale [18] using reversed-phase ultra-performance liquid 
chromatography tandem mass spectrometry (UPLC-MS/MS).
Extraction efficiency and ionization suppression
To achieve a level of ruggedness required for consistently reliable 
analysis of sequential batches, several important parameters 
were carefully optimized in the LLE procedure. Even after cen-
trifugation, removal and usage of the ethyl acetate-hexane layer 
near the plasma interface was shown to be detrimental to assay 
ruggedness and to increase ionization suppression. A careful 
removal of the solvent layer produced a very clean extracts that 
resulted in no significant ionization suppression and a rugged 
analysis method. A back extraction step was not used, but rather 
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the ethyl acetate-hexane was evaporated and the extract was 
reconstituted in acetonitrila-water (90:10, v/v) with 0.1 % of for-
mic acid. These conditions increased sample throughput and 
proved to be very rugged and reliable, with thousands of plasma 
extracts typically injected on a single HPLC column.
Methods for high rates of bioanalytical sample analysis of finas-
teride using a liquid chromatography coupled to a tandem mass 
spectrometry analysis have also been reported in the literature 
[14–19]. Our method showed the best relation between LLOQ 
and chromatographic run time. The work of Phapale et al. [18] 
presented exactly the same LLOQ of 0.1 ng/mL, but the chroma-
tographic run time was 3 min. Less sensitive analytical methods 
describing the quantification of finasteride in human plasma 
using mainly UV detection methods have also been reported 
[8–13].
Finasteride showed the recoveries (values ± CV( %), n = 5) for QCL, 
QCM and QCH in normal human plasma as follows: 74.2 ± 17.7 %, 
95.8 ± 13.1 % and 80.6 ± 14.8 %, respectively. The recovery of the IS 
was 61.8 ± 19.5 %. Similar recovery values were obtained for 
hemolized and lipemic plasma.
These efficiencies may also include losses due to the extract sol-
vent lost after freezing and transferring steps. However, method 
optimization revealed that attempting removal of the residual 
extraction solvent introduced contaminants that resulted in 
increasing HPLC back pressure and degradation of analyte peak 
shapes after a few hundred injections. However, with stable-
labeled internal standards to compensate for analyte losses, the 
accuracy and precision remained excellent and sensitivity was 
not significantly compromised.
The ionization suppression was assessed in an attempt to evalu-
ate additional potential sources of signal loss. In this assays, the 
MS/MS responses from the analysis of spiked, blank plasma sub-
jected to the preparation procedure were compared with the 
analogous responses obtained from neat solutions. In all cases, 
the ratio of the peak areas measured from the plasma analysis 
compared to those obtained from the solvent diluted com-
pounds (values ± CV( %), n = 5) for QCL, QCM and QCH in normal 
human plasma were as follows: 96.1 ± 13.3 %, 97.7 ± 13.2 % and 
98.8 ± 10.2 %, respectively. The result for the IS was 94.5 ± 6.4 %.
Since the current experiment measures extraction efficiency 
plus all additional sources of signal loss, these results indicate 
that after accounting for losses due to recovery from plasma, 
there are no other significant sources of response loss, including 
ionization suppression. These data also provide additional evi-
dence that the sample preparation conditions produce very 
clean sample extracts.
Selectivity and lower limit of quantification
During validation, analysis of 6 individual sources of normal 
human plasma produced no response for finasteride or betame-
thasone dipropionate. None of the 6 plasma sources resulted in 
quantifiable responses for both molecules. In addition, through-
out clinical study sample analysis, pre-dose samples did not 
generate a significant response for the analyte or the internal 
standard, showing no contamination or insufficient wash-out 
period from previous dosage of medication.
The LLOQ for the method was established at 0.1 ng/mL and the 
signal-to-noise ratio was higher than 7. The SRM chromato-
grams obtained from extracted blank plasma simultaneously 
spiked with the LLOQ calibration standard and the internal 
standard are shown in  ●▶ Fig. 2, showing typical analyte signal-
to-noise ratios achieved at this concentration. Analysis of study 
samples produced similar chromatographic results with no 
additional peaks observed.
There was no interfering peak when the analysis was performed 
using two other batches of hyperlipemic and hemolyzed plasma 
Fig. 2	 MRM	chromatograms	of	human	plasma	samples	spiked	with	finasteride	and/or	betamethasone.	The	monitoring	channels	were	m/z 373.5 > 305.2 
for	finasteride	transition	and	m/z 505.3 > 411.2 for betamethasone transition. a	Comparison	of	blank	plasma	samples	without	(upper)	or	with	finasteride	
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( ●▶ Fig. 3). In addition, there was no significant ion suppression 
in the region where the analyte and internal standard are eluted.
Linear dynamic range and over-range samples
The simplest regression method for the calibration curves 
for finasteride quantification was Y = a + bx(1/x2) from 0.1 to 
25.0 ng/mL. Including all the calibration curves from the valida-
tion process and the quantification of samples from the pharma-
cokinetic study, the correlation coefficient ranged from 0.9958 
to 0.9989. To fit the calibration data, a 1/x2 linear function was 
used during analysis.
Accuracy and precision
The intra- and inter-batch precision (expressed as percent CV) 
and accuracy were established from validation runs performed 
at QCL, QCM and QCH ( ●▶ Table 1) and throughout analysis of all 
clinical study batches. The intra-batch precision and accuracy 
were also determined for the LLOQ levels. The intra-batch preci-
sion ranged from 3.6 to 7.1 % and the accuracy was within 96.6–
103.9 %. For the inter-batch experiments, the precision ranged 
from 2.5 to 3.4 % and the accuracy was within 100.3–103.5 %. 
These results indicate excellent accuracy and precision at all 
quantification levels, as these data easily exceeded the guidance 
established accuracy criteria of  ± 15 % for the QC levels (± 20 % at 
the LLOQ) with target CV values of  ≤ 15 % (≤ 20 % at the LLOQ).
Autosampler carry-over
Injection of a diluent blank immediately following analysis of 
the highest calibration standard resulted in no observed 
response for finasteride.
Stability
Analyte stability was investigated for a variety of conditions that 
were utilized for handling and storage of both standards and 
samples. Stability was confirmed if after exposure to a given 
condition for a period of time, average measured analyte con-
centrations were below 15 % of variation compared to their 
respective spiked concentrations. Results of the stability studies 
are summarized in  ●▶ Table 2.
Fig. 3	 Specificity	of	the	response	for	the	interfering	peaks	at	the	retention	time	for	finasteride	and	betamethasone	after	the	UPLC.	MRM	Chromatograms	
of	blank	plasma	samples	at	both	finasteride	(upper	panel)	and	betamethasone	(lower	panel)	channels:	a normal plasma; b hyperlipemic and c hemolyzed 
plasma sample.
Table 1	 Accuracy	and	precision	data	for	finasteride	quantification	in	human	plasma.	Results	were	obtained	during	the	validation	of	QC	samples,	including	the	
LLOQ in human plasma.
QC samples Nominal concentration  
(ng/mL)
Intra-run accuracy a 
(%)
Inter-run accuracy b 
(%)




QC-LLOQ 0.1 96.6 112.9 7.1 5.8
QCL 0.3 102.1 103.5 5.5 2.7
QCM 10.0 101.4 100.3 6.3 2.5
QCH 20.0 103.9 102.4 3.6 3.4
a (n = 6), expressed as (found concentration/nominal concentration) × 100
b Values obtained from all 3 runs (n = 18)
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Freeze/thaw cycles were investigated to assure that no analyte 
losses occurred during the sample freezing and thawing that 
were required for analysis and possible sample retests. Both the 
analyte and the IS were shown to be stable for as many as 3 
freeze/thaw cycles with temperature changes from ambient 
to  − 20 °C followed by a return to room temperature. Short-term 
storage of plasma at room temperature on the bench top was 
evaluated to simulate worst case exposure to room temperature 
after thawing and during possible delays in the sampling process 
prior to refreezing. Analyte stability was demonstrated for upto 
23 h under these conditions. For prepared samples, stability was 
established to insure that during the time of analyses of one ana-
lytical batch stored in the auto injector, prepared samples could 
remain stable under the equipment conditions upto 25 h, 
defined as the maximum time to analyze the longest analytical 
batch in this study. Long-term storage stability was evaluated 
after 185 days to cover the total period that samples remained 
frozen at  − 20 °C during the complete study. Plasma samples 
spiked with finasteride at QCL and QCH concentrations showed 
a variation of  − 10.9 % and  − 2.4 %, respectively.
These studies also demonstrated that finasteride and the IS are 
stable in spiking solutions of acetonitrile-water (70:30, v/v) 
when stored in polypropylene cryovials at room temperature for 
10 h or 3 days at 4 °C. The finasteride work solutions showed 
only  − 1.5 % variation between fresh and stored samples at room 
temperature after 10 h. Similarly, the finasteride work solutions 
stored at 4 °C showed a variation of 1.3 % after 3 days. The IS work 
solutions showed variation of  − 2.1 % after 10 h at room tempera-
ture and  − 5.1 % after 3 days at 4 °C.
Pharmacokinetic results
This method was applied to evaluate the comparative bioavaila-
bility in 78 healthy volunteers. All volunteers received a single 
1.0 mg tablet orally corresponding to the test finasteride or ref-
erence formulation, following an open, 2-period, balanced rand-
omized, crossover protocol.
Mean plasma concentration vs. time profiles for finasteride fol-
lowing oral administration of 2 formulations are displayed 
in  ●▶ Fig. 4. The plasma concentration of finasteride did not dif-
fer significantly after administration of both formulations.
Finasteride was well tolerated at the administered doses and no 
significant adverse reactions were observed or reported. No clin-
ically relevant change was observed in any measured biochemi-
cal parameter. A total of 38 volunteers finished the study.
 ●▶ Table 3 shows the values of the pharmacokinetic parameters 
and  ●▶ Table 4 summarizes the bioequivalence analysis for finas-
teride formulations. Briefly, the geometric mean and respective 
90 % CI of finasteride test/reference percent ratios were 97.68 % 
(91.23; 104.60 %) for Cmax and 97.51 % (92.08; 103.27 %) for AUC0-t.
Conclusions
▼
This work describes a fast, sensitive and robust method to quan-
tify finasteride in human plasma using betamethasone as the 
internal standard. The sample preparation described in this 
Table 3 Arithmetic mean pharmacokinetic parameters obtained from 38 
volunteers	after	administration	of	each	1.0	mg	finasteride	tablet	formulation.
Test formulation Reference formulation
Mean SD Mean SD
Cmax (ng/mL) 6.97 3.19 7.32 3.87
Tmax (h) 2.37 0.98 1.86 0.82
T1/2 (h) 4.75 1.92 4.14 1.24
AUClast ([ng × h]/mL) 41.46 22.67 42.77 22.22
AUCinf ([ng × h]/mL) 43.58 23.46 44.56 22.58
Table 4 Geometric mean of the individual AUClast, AUC0–inf and Cmax ratios 
(test/reference formulation) and the respective 90 % CIs.
Parameters
Parametric (n = 57)
Geometric 
mean (%) 




Cmax  % ratio 97.68 91.23; 104.60 99 % 17.79
AUClast  % ratio 97.51 92.08; 103.27 99 % 14.88
AUCinf  % ratio 98.07 92.67; 103.78 99 % 14.69
Fig. 4	 Finasteride	plasma	mean	concentration	vs.	time	profiles	obtained	
after	the	administration	of	1.0	mg	finasteride	test	or	reference	formula-
tions. Results are expressed as mean ± SEM.
Table 2	 Stability	tests	of	finasteride	in	human	plasma.
Initial mean conc. (ng/mL)  % CV Final mean conc. (ng/mL)  % CV Variation ( %)
Freeze and thaw stability test (3 cicles)
QCL 0.303 11.6 0.323 11.6 6.51
QCH 18.9 13.3 20.9 8.74 10.88
Short Term stability test (23 h)
QCL 0.303 11.6 0.307 6.54 1.21
QCH 18.9 13.3 20.6 6.11 9.21
Post Processing stability test (25 h)
QCL 0.303 11.6 0.314 12.0 	−	2.9
QCH 18.9 13.3 19.1 12.8 0.2
n = 3 for each test
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work produces very clean extracts and provides excellent rug-
gedness of the LC-MS/MS analysis with virtually no ionization 
suppression. The analytical method described in this work offers 
the advantage over those previously reported using LC-MS/MS 
showing a very low validated LLOQ (0.1 ng/mL) associated with a 
faster chromatographic run time (2.0 min).
The described method for finasteride quantification in human 
plasma was successfully applied in a bioequivalence study of 
two finasteride 1.0 mg tablet formulations using an open, rand-
omized, 2-period crossover design. Since the 90 % CI for Cmax and 
AUC ratios were all inside the 80–125 % interval, it was con-
cluded that the test formulation of finasteride is bioequivalent to 
the reference formulation with respect to both the rate and the 
extent of absorption.
This example of PK results demonstrate the utility of this meth-
odology, and bioanalytical measurements in general, for design-
ing superior products and confirming their performance by 
measuring drug delivery and correlating with biological efficacy.
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